OCC 4.38% 65.5¢ orthocell limited

Ann: Quarterly Activity Report & Appendix 4C, page-30

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,895 Posts.
    lightbulb Created with Sketch. 7130
    ....yeah, sorry guys. Spent a few hours looking at this and just cannot mathematically reverse engineer any convincing unit pricing from OCC's Appendix 4C's. No matter how I vary the lags on cash accounting receipts vs units sales given and base organic sales exclusive of DVT and BH, it just doesn't give a convincingly symmetry with realistic unit prices generated revenues vs cash flows.

    This will be easier to do once we get the formal full year accrual accounting results. Its like the accounting dept. went on holiday in 3Q23 and didn't bother collecting cash. One thing is glaring. The cash receipts for the increased sales have not remotely hit yet, unless Striate is being sold for a dollar or pre-existing sales exclusive of BH are of larger numbers (alas we know that's not true):
    FY23 Striate units via BH10936


    FY23 Remplir units via DVT682









    FY23





    Qtr
    SriateRemplir
    Cash revenues (k)(FY22)
    4
    5482362
    645407
    3
    2339100
    265313
    2
    272636
    500378
    1
    389184
    463356







    FY23
    10936682018731454









    OCC increased its BH Striate sales by 1300% 4Q to 1Q and Remplir by 96% and yet receipts go from only $463K to $645K QoQ? Suspect the forthcoming full year results revenues, that will of course be accounted on an accrual basis, are going to dwarf the reported full year sales receipts that are calculated on a cash flow basis - otherwise something is up with their accounting/reporting.

    Even if you went with Jonesing's lowest base gross prices of $45 and $812 for Striate and Remplir, the increase of accrued revenues between the two would be $374K - and $648K at the upper end of the range. Similarly only $645K vs $407K, 4QFY23 vs 4QFY22 after an explosion in relative sales in BH Striate sales across the two. Clearly these unit sales increases have not shown in cash receipts in any remotely consistent fashion in the Appendix 4C's, and a significant portion appear yet reflected at all in accounting figures to date vs reported sales increases.

    Me thinks some impressive full year accounts coming our way. An interesting lesson in accrual accounting vs the cash flows - you have to look at both.



 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
(20min delay)
Last
65.5¢
Change
-0.030(4.38%)
Mkt cap ! $156.6M
Open High Low Value Volume
67.0¢ 67.0¢ 65.0¢ $239.3K 362.1K

Buyers (Bids)

No. Vol. Price($)
1 10000 65.5¢
 

Sellers (Offers)

Price($) Vol. No.
66.0¢ 4477 2
View Market Depth
Last trade - 15.58pm 13/11/2024 (20 minute delay) ?
OCC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.